About Pharmaron
Pharmaron is a publicly listed company based in Beijing (China) founded in 2003 by Larry Lou, Bei Zheng, and Boliang Lou. Drug discovery and development services for small molecules are provided. Pharmaron has raised $320 million across 5 funding rounds from investors including HHS, CITIC Capital and Legend Capital. The company has 476 employees. Pharmaron has completed 6 acquisitions, including Absorption, Aesica and Allergan. Its chief executive, as recorded, is Boliang Lou. Its website pharmaron.com draws about 46 thousand monthly visits. Its focus areas include Biopharma Outsourcing, Diversified and Small Molecules & Peptides.
Company details
Founded in 2003 and headquartered in Beijing, China, Pharmaron operates in the pharmaceutical sector, focusing on research and development services for small molecules, nucleosides, nucleotides, peptides, lipids, and carbohydrates. Disciplines covered include chemistry, biology, DMPK, pharmacology, toxicology, and formulation development. Expertise encompasses organic synthesis, medicinal chemistry, biologics engineering, protein expression, and purification. Acquisitions of Xceleron and SNBL CPC have expanded the service portfolio.
- Headquarters Beijing, China
- Employees 476
- Founders Larry Lou, Bei Zheng, Boliang Lou
- Stage Public
- SectorsHealthcare
- Website pharmaron.com
- Social LinkedIn X
- Total Equity Funding$320M (USD)
in 5 rounds
- Latest Funding Round$280M (USD), Private Equity Round
Dec 2015
- InvestorsHHS
& 5 more
- Employee Count476
- Investments & AcquisitionsAbsorption
& 5 more
Funding Insights of Pharmaron
Pharmaron has successfully raised a total of $320M across 5 strategic funding rounds. The most recent funding activity was a Private Equity Round of $280 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $320M
- Total Rounds 5
- Last Round Private Equity Round — $280M
- First Round $214,696
(Sep 2008)
- Investors Count 6
All 5 funding rounds of Pharmaron with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2015 | $280M | Private Equity Round | – | Legend Capital | |
| Mar 2011 | $40M | Series C | – | Gl-investment | |
| Sep 2009 | $818,323 | Grant | – | – | |
| Sep 2009 | $818,323 | Grant | – | – | |
| Sep 2008 | $214,696 | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Pharmaron
Pharmaron has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, CITIC Capital and Legend Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture Capital firm focused on multiple sectors | legendcapital.com.cn | Haidian, China | ||
Tech-focused seed, early, and mid-stage VC investments are made globally. | dcm.com | Menlo Park, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Commercial ecological platform projects are targeted by this corporate fund. | 2002 | citiccapital.com | Hong Kong, China | |
GL Capital is focused on healthcare sector value investments. | gl-investment.com | Beijing, China | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Pharmaron
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pharmaron
287 people are tracked at Pharmaron (137 in leadership, 150 in team); the tracked headcount is 476.
| Name | Role | Group |
|---|---|---|
Larry Lou | Co-Founder | Leadership |
Bei Zheng | Co-Founder | Leadership |
Boliang Lou | Co-Founder & CEO | Leadership |
Chad McRoberts | Director Of Quality Assurance | Leadership |
Derek Ellison | Vice President Biologics Services, Europe | Leadership |
Grant Johnston | Senior Director, Chemistry | Leadership |
Su Qian | VP, Disease Biology | Leadership |
Cliff Wu | Executive Director, Chemical Manufacturing | Leadership |
Rob Norris | Head Of Engineering | Leadership |
Venkata Ramana Raju.n | Director - Technology Operations | Leadership |
Martin Swarbrick | Senior Director, Head Of Chemistry | Leadership |
Howe Li | Chief Medical Officer | Leadership |
Kate Patterson | Associate Director, Bioanalytical | Leadership |
Hua Yang | Chief Scientific Officer | Leadership |
Gilbert Li | Chief Financial Officer | Leadership |
Lorraine Lu | Senior Director Business Development | Leadership |
Paolo Depetrillo | Medical Director | Leadership |
Jeremy Scott | VP, Process Chemistry | Leadership |
Zhenhua Zhou | VP, Head of Quality, CMC | Leadership |
Katherine Lee | Chief Business Officer | Leadership |
267 more people are available in the full profile.
Complete people profiles for Pharmaron
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pharmaron
Pharmaron has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Absorption, Aesica and Allergan.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Contract development and manufacturing organisation (CDMO) for APIs and finished dose forms | aesica-pharma.com | Newcastle Upon Tyne, United Kingdom | 2004 | Jan 2023 | •••• | |
A portfolio of generic medicines is developed and manufactured. | allergan.com | Madison, United States | 1948 | Mar 2021 | $118.7M | |
Integrated preclinical research services for drugs and devices are provided. | absorption.com | Exton, United States | 1996 | Nov 2020 | $137.5M | |
Full service, early phase CRO specializing in complex trials | snbl-cpc.com | Baltimore, United States | 2006 | Feb 2017 | •••• | |
Accelerator Mass Spectrometry is utilized by Xceleron for pharmaceutical analysis. | xceleron.com | Germantown, United States | 1997 | Jan 2017 | •••• | |
Early-stage drug development services are provided by this CRO. | quotientbioresearch.com | Rushden, United Kingdom | 1992 | Feb 2016 | •••• |
Complete acquisition details for Pharmaron
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Pharmaron
10 dated milestones of Pharmaron across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Pharmaron is founded.
- Funding First funding round of $215K.
- Funding Latest funding round, Private Equity Round, of $280.0M.
- Acquisition Acquires Quotient Bioresearch.
- Acquisition Acquires Xceleron.
- Acquisition Acquires SNBL Clinical Pharmacology Center.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Absorption.
- Acquisition Acquires Allergan.
- Acquisition Acquires Aesica.
Web traffic of Pharmaron
The website of Pharmaron (pharmaron.com) receives about 45.6K visits a month.
- Monthly visits45.6K
▲ 7.3% vs previous month
Websites whose visitors overlap most with Pharmaron. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| synomicspharma.com | 100% | View details | |||
| diteba.com | 98% | View details | |||
creative-biolabs.com | creative-biolabs.com | 68% | #348,062 | – | |
| mpiresearch.com | 61% | View details | |||
| abzena.com | 60% | 14.8K | #1,542,256 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Pharmaron
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharmaron
Complete news archive for Pharmaron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharmaron
Pharmaron was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Pharmaron is headquartered in Beijing, China.
Boliang Lou is the CEO of Pharmaron, as recorded in our data. They have also founded this company.
Pharmaron is a funded company, having raised a total of $320M across 5 funding rounds to date. The company's 1st funding round was a Grant of $214.7K, raised on Sep 2008.
Pharmaron has 476 employees.
Founded in 2003 and headquartered in Beijing, China, Pharmaron operates in the pharmaceutical sector, focusing on research and development services for small molecules, nucleosides, nucleotides, peptides, lipids, and carbohydrates. Disciplines covered include chemistry, biology, DMPK, pharmacology, toxicology, and formulation development. Expertise encompasses organic synthesis, medicinal chemistry, biologics engineering, protein expression, and purification. Acquisitions of Xceleron and SNBL CPC have expanded the service portfolio.
Pharmaron has made 6 acquisitions, including Absorption, Aesica, and Allergan.
Pharmaron has 6 investors. Key investors include HHS, CITIC Capital, Legend Capital, DCM, and Aisling Capital.